Hospital
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center was paid $4.43M by Medicaid between Jan 2018 and Dec 2024, across 134 billing codes. Its largest line is 99232, hospital visit by a doctor, follow-up day — 22% of everything it billed.
33Billing provider infoCEDARS-SINAI MEDICAL CENTER
LOS ANGELES, CA 90048
LOS ANGELES, CA 90048
33aNPI1528263746assigned 06/18/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.43M
24GClaims176,125
24DCodes billed134
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#233 of 410
Median peer was paid$6.90M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,866 | $335K | |
| 2019 | 17,862 | $513K | |
| 2020 | 25,781 | $633K | |
| 2021 | 37,730 | $1.18M | |
| 2022 | 29,618 | $770K | |
| 2023 | 26,930 | $660K | |
| 2024incomplete | 15,338 | $345K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 22% | 23,005 | 8,635 | $963K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 6,077 | 6,025 | $550K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 7.8% | 6,392 | 6,301 | $348K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 6.1% | 30,106 | 18,559 | $271K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 5.6% | 4,151 | 1,896 | $248K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 4.9% | 1,618 | 606 | $216K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 1,239 | 1,221 | $145K |
| 0120 | 3.2% | 107 | 94 | $140K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.7% | 5,020 | 4,109 | $122K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 806 | 776 | $118K |
| 0450 | Emergency room services | 2.5% | 5,292 | 4,730 | $109K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 2,708 | 2,450 | $90K |
122 more codes
| 93970 | 1.8% | 2,377 | $81K | |
| 99223 | Prolong inpt eval add15 m | 1.6% | 786 | $72K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 728 | $64K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 2,265 | $52K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 3,481 | $48K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 610 | $43K |
| 99221 | <1% | 4,272 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,932 | $38K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,118 | $33K |
| 0250 | <1% | 5,137 | $33K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 945 | $31K |
| A4649 | Surgical supply; miscellaneous | <1% | 1,597 | $26K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 319 | $25K |
| 0301 | <1% | 382 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,416 | $22K |
| 99283 | Emergency room visit (moderate) | <1% | 594 | $21K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,293 | $20K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 454 | $20K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 400 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,778 | $20K |
| 0272 | <1% | 523 | $19K | |
| 0710 | <1% | 233 | $19K | |
| 86850 | <1% | 245 | $17K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 638 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,981 | $15K |
| 80053 | Comprehensive metabolic panel | <1% | 2,109 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 605 | $14K |
| 80076 | <1% | 3,040 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 854 | $12K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 400 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 214 | $11K |
| 0949 | <1% | 720 | $11K | |
| G0378 | Hospital observation service, per hour | <1% | 636 | $11K |
| 84484 | <1% | 2,504 | $11K | |
| 86900 | <1% | 474 | $11K | |
| 83880 | <1% | 857 | $10K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 163 | $10K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,829 | $10K |
| 0510 | <1% | 932 | $8K | |
| 0206 | <1% | 49 | $8K | |
| 81001 | <1% | 3,749 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 560 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 310 | $7K |
| 0370 | <1% | 162 | $7K | |
| 83690 | <1% | 2,215 | $6K | |
| 84703 | <1% | 1,489 | $6K | |
| 0305 | <1% | 404 | $5K | |
| 0762 | <1% | 93 | $5K | |
| 94375 | <1% | 538 | $4K | |
| 87088 | <1% | 606 | $4K | |
| 86901 | <1% | 486 | $4K | |
| 83605 | <1% | 676 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 40 | $3K |
| 99254 | <1% | 38 | $3K | |
| 93971 | <1% | 203 | $3K | |
| 49083 | <1% | 42 | $3K | |
| 96376 | <1% | 334 | $3K | |
| 85610 | <1% | 1,314 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,200 | $2K |
| 0352 | <1% | 76 | $2K | |
| 87040 | <1% | 273 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $2K |
| 0300 | <1% | 285 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 57 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 894 | $2K |
| 85730 | <1% | 751 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| J3490 | Unclassified drugs | <1% | 1,744 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 850 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 270 | $2K |
| 73610 | <1% | 53 | $1K | |
| 83735 | <1% | 426 | $1K | |
| 0324 | <1% | 171 | $1K | |
| 93308 | <1% | 48 | $1K | |
| 0306 | <1% | 362 | $955.29 | |
| 0730 | <1% | 172 | $914.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 186 | $897.72 |
| 87077 | <1% | 222 | $823.18 | |
| 87400 | <1% | 118 | $806.16 | |
| 93325 | <1% | 222 | $650.92 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 512 | $620.38 |
| 0760 | <1% | 15 | $619.04 | |
| 0271 | <1% | 199 | $609.49 | |
| 94729 | <1% | 83 | $562.95 | |
| 94726 | <1% | 69 | $548.12 | |
| 0761 | <1% | 53 | $537.80 | |
| 85027 | <1% | 104 | $477.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 70 | $466.54 |
| 93321 | <1% | 57 | $447.87 | |
| 0255 | <1% | 110 | $394.78 | |
| 85379 | <1% | 79 | $267.47 | |
| 84100 | <1% | 38 | $236.35 | |
| 86140 | <1% | 121 | $234.51 | |
| 80306 | <1% | 70 | $225.94 | |
| J2704 | Injection, propofol, 10 mg | <1% | 52 | $215.49 |
| 0302 | <1% | 100 | $179.85 | |
| 73630 | <1% | 15 | $173.05 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 20 | $169.36 |
| 80197 | <1% | 39 | $152.61 | |
| 85652 | <1% | 110 | $127.49 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 40 | $121.35 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 30 | $111.33 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $77.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 31 | $51.86 |
| 87186 | <1% | 13 | $49.91 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 59 | $48.12 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 36 | $38.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $24.61 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12 | $23.82 |
| 82962 | <1% | 19 | $23.68 | |
| 80061 | Lipid panel | <1% | 15 | $22.62 |
| 80320 | 0% | 97 | $0.00 | |
| 0001A | 0% | 129 | $0.00 | |
| 0307 | 0% | 112 | $0.00 | |
| 0031A | 0% | 12 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 15 | $0.00 |
| 0483 | 0% | 30 | $0.00 | |
| 0637 | 0% | 243 | $0.00 | |
| 0309 | 0% | 48 | $0.00 | |
| 0320 | 0% | 28 | $0.00 | |
| 0002A | 0% | 125 | $0.00 | |
| 0424 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGORDON, THOMAS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles, CA | $216K |
| Specs, PA | South Casco, ME | $128K |
| Cedars-Sinai Medical Center | Los Angeles, CA | $92K |
| Cedars-Sinai Medical Center | Los Angeles, CA | $30K |
| Cedars-Sinai Medical Center | Los Angeles, CA | $1K |
| Cedars-Sinai Medical Center | Los Angeles, CA | $753.06 |
| Medical Group of Beverly Hills | Los Angeles, CA | $31.60 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.